Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 8/20 | 0.54 |
| ▸ | RHOC | P08134 | 7/20 | 0.54 |
| ▸ | TACR1 | P25103 | 6/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PRLHR | P49683 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405395 | 0.89 | CYP3A4 (0.47) | RHOARHOCTACR1MGLLUSP2 | |
| SCHEMBL6414888 | 0.76 | TACR1 (0.54) | TACR1CYP3A4 | |
| SCHEMBL5010693 | 0.75 | RHOC (0.61) | RHOARHOCMGLL | |
| SCHEMBL6408955 | 0.73 | TACR1 (0.49) | TACR1 | |
| SCHEMBL1534297 | 0.73 | HIF1A (0.58) | RHOARHOCUSP2CYP3A4CYP2C9 | |
| SCHEMBL6439965 | 0.72 | RHOA (0.54) | RHOARHOCTACR1MGLL | |
| SCHEMBL6440962 | 0.72 | RHOA (0.54) | RHOARHOCTACR1MGLL | |
| SCHEMBL6442198 | 0.72 | RHOA (0.55) | RHOARHOCMGLLUSP2CYP3A4 | |
| SCHEMBL12803227 | 0.72 | RHOC (0.57) | RHOARHOCTACR1MGLLUSP2 | |
| SCHEMBL9565788 | 0.71 | RHOC (0.48) | RHOARHOCTACR1MGLLUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | BDKRB1, BDKRB2, TACR1 | RHOA 3912/4885RHOC 3762/4885TACR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.